Navigation Links
Boehringer Ingelheim's investigational volasertib receives FDA Breakthrough Therapy designation
Date:9/17/2013

is intensive chemotherapy to induce disease remission, followed by consolidation/maintenance chemotherapy. However, many patients over 65 years of age – whose prognosis is typically poor7 – are ineligible for this approach, which involves large doses of chemotherapy over short periods of time,6 and therefore have even fewer treatment options. Volasertib* is currently being investigated in this specific patient population.8

Results from a Phase II study, in newly diagnosed patients with AML considered ineligible for intensive remission induction therapy, demonstrated higher rates of objective response and an improvement in event-free survival in patients receiving volasertib in combination with low-dose cytarabine (LDAC) compared to patients receiving LDAC alone.9 The results were presented at the 54th American Society of Hematology (ASH) annual in December 2012.9

These results led to the initiation in January 2013 of a Phase III trial, POLO-AML-2 (Clinical Trial Identifier: NCT01721876).8 This trial is designed to assess the efficacy and safety of volasertib in combination with LDAC, compared to placebo in combination with LDAC, in patients aged 65 or older with previously untreated AML, ineligible for intensive remission induction therapy.8 The trial is currently enrolling eligible patients.8 For more information please visit ClinicalTrials.gov.8

About Volasertib
Volasertib, an investigational inhibitor of polo-like kinase (Plk), is one of several late-stage compounds that Boehringer Ingelheim is currently evaluating in clinical trials for various solid tumors and hematological cancers. Boehringer Ingelheim is one of the first companies
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
2. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
3. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
4. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
6. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
7. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
8. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
9. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
10. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
11. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... GABLES, Fla. , Nov. 20, 2014   ... to become the first U.S. commercial producer of Molybdenum-99 ... a contract with INVAP to design its ... Fla. Mo-99 is the parent isotope of ... medicine procedures worldwide. In 2012, Congress passed legislation making ...
(Date:11/21/2014)...   Wellcentive , the industry leader in ... announced today being named one of the four ... .  Sponsored by Intel, the world leader in ... recognizes companies developing leading-edge technology and unique approaches ... Wellcentive,s Mason Beard , senior ...
(Date:11/21/2014)... 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... offering of $80,000,000 aggregate principal amount of 5.25% Convertible ... private offering within the United States ... buyers pursuant to Rule 144A under the Securities Act ... also granted the initial purchasers an option to purchase ...
Breaking Medicine Technology:Coqui RadioPharmaceuticals Inks Deal With INVAP 2Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3
... Results Reported at American Association for Dental Research ... Parion Sciences, Inc., a,privately-held, development-stage pharmaceutical company dedicated ... body,s mucosal,defenses, today announced preliminary results from a ... channel blocker, P-552-02, as a topical,therapy for dry ...
... April 7 A biosimilar product for,treating the ... the,white blood cells of patients is safe and ... a reference,product. This is the result of a ... company Kwizda Pharma GmbH and the Indian manufacturer,INTAS ...
Cached Medicine Technology:Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment 2Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment 3Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 2Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 3
(Date:11/22/2014)... Sandbridge Capital, a private equity ... consumer brand sector, acquired a minority stake in ... to help fund BackJoy’s global growth and accelerate ... proprietary apparel and footwear lines. Sandbridge Capital Managing ... Directors. , BackJoy is a high-growth health and ...
(Date:11/22/2014)... Columbus, OH (PRWEB) November 22, 2014 ... trials for AndroGel side-effects lawsuits have been scheduled ... District Court, Northern District of Illinois. U.S. District Judge ... litigation, issued a Case Management Order (CMO) on November ... as deadlines for attorneys to submit documents and other ...
(Date:11/22/2014)... News) -- Those air-blown hand dryers in public restrooms ... a new study suggests. British researchers placed a ... in order to simulate poorly washed hands. They then ... paper towels to dry their hands. The investigators ... germs around both types of dryers than around towel ...
(Date:11/21/2014)... Haven, CT (PRWEB) November 21, 2014 ... added a veteran radio industry sales professional to its ... Disney, brings 30 years of leadership and sales experience ... office and assume the title of Director of Strategy ... and Development, Robert O’Mara. , Heinemann will handle a ...
(Date:11/21/2014)... 2014 (HealthDay News) -- The cost of diabetes care ... recent years, climbing to more than $322 billion annually, ... cost were seen with prediabetes care, which have risen ... percent, the researchers added. In 2012, excess medical ... than $1,000 for every American. That total includes $244 ...
Breaking Medicine News(10 mins):Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2Health News:Radio Industry Veteran Joins CRN International’s Sales Organization in Detroit 2Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2
... following ace cricketer Sachin Tendulkar's and several other players complaining ... the sports arena//. ,Tennis elbow, or lateral epicondylitis ... where the outer part of the elbow becomes painful and ... or a direct bang. The problem occurs following overuse of ...
... with type-2 diabetes are at high risk of ... events are the main reason for their decreased ... of peroxisome proliferator-activated receptor-? (PPAR-?) could reduce macrovascular ... treat type-2 diabetes. ,A recent study, published ...
... an independent risk factor for cardiovascular disease in both ... fold relative to nondiabetic subjects and that 80 percent ... of an atherosclerotic event//. In these patients ... and so the presence of even borderline-high-risk LDL-C signals ...
... capable of altering the emotional state of humans. Physiological ... in folk medicine and aromatherapy for a long time//. ... mood enhancing properties by aromatherapists. ,Recently a study, ... & Behavior, was undertaken to investigate the impact of ...
... the benefits of oral ZYVOX for the treatment of ... compared data from 80 health care clinics and compared ... The results show that oral tablets of Linezolid (ZYVOX), ... to health clinics compared to vancomycin. ,This ...
... have reconstructed defective windpipes using tissue engineering in ... growing the sections of cartilage tube // and ... they were in the womb. This technique of ... Undifferentiated stem cell from amniotic fluid, which is ...
Cached Medicine News:Health News:Tennis elbow not new among cricketers, say experts 2Health News:Aromatherapy: Ambient odors of orange and lavender reduce anxiety 2Health News:Oral use of ZYVOX (Linezolid) is better to Intravenous Vancomycin use for Skin Infections 2
... is a SmartBeam platform providing high-performance scanning and ... most vital clinical sites - spine and femur ... ,The full-function DPX Bravo densitometer gives you a ... You can place it in almost any room ...
... System consists of the portable AutoPulse Platform, ... rechargeable battery pack with a state-of-the-art recharger. ... adults with weight up to 300 lbs ... inches (76 to 130 cm) and chest ...
... is an integrated system that will perform ... want it. You no longer need to ... arterial inflow with and without reactive hyperemia ... the time for measurements and the frequency ...
... System combines cutting edge technology with proven Hokanson ... package available in the US and Canada. ,The ... to do vascular examinations in the same order ... waveforms and data in a database. Tests are ...
Medicine Products: